Oral PDE5 Inhibitors rarely cause priapism, finds study
Prescribe Generic Medicine
USA: Phosphodiesterase type 5 inhibitor (PDE5i)-induced priapism is a rare event, according to a recent study published in the Journal of Sexual Medicine. The study suggests that PDE5i-induced priapism occurs but is less common than suspected. Drug-induced priapism should be attributed to a wider spectrum of medications that can cause this condition.
Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction.
Michael E. Rezaee and Martin S. Gross from Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, conducted the study with an aim to identify the true data about PDE5i-associated priapism to properly counsel patients.
The researchers queried the U.S. Food and Drug Administration (FDA) Adverse Reporting System Public Dashboard to identify cases of drug-induced priapism among medications commonly associated with priapism. Then they carried out a systematic review and analysis of publications describing cases of drug-induced priapism.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.